BostonGene-Integrated Genomic Registry (BIGR)

Launched by BOSTONGENE · Jul 28, 2021

Keywords

ClinConnect Summary

The BostonGene-Integrated Genomic Registry (BIGR) trial is a research project aimed at improving the understanding of cancer by collecting detailed information about patients with malignancies, which means cancer. The main goal is to create a large database that includes genetic and clinical information from cancer patients. Researchers hope that by studying this data, they can identify important markers that could lead to better treatments and outcomes for various types of cancer in the future.

To participate in this trial, you need to be an adult living in the United States with suspected or confirmed cancer. You should also be planning to undergo a comprehensive genetic test, or have had one in the past. Participants will need to agree to stay in touch with the study team to share information about their cancer treatment and progress. It’s important to note that if you have a life expectancy of less than three months, you wouldn’t be eligible for this trial. If you join, you will be contributing to vital research that could help many people facing cancer down the line.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • 1. Suspected or confirmed malignancy
• • 2. Planned comprehensive genomic (\> 100 genes) and/or molecular analysis; or genomic and/or molecular data available from prior sequencing
• • 3. Baseline demographics and treatment information available
• • 4. Willingness for future contact by BIRG study personnel to provide information regarding associated cancer outcomes and treatment.
• • 5. Signed informed consent to participate in the study.
• • 6. Living in the United States at the time of enrollment
• Exclusion Criteria:
• • Life expectancy \< 3 months